HomeMembershipLogin MembershipSomme Cancer Registry
Somme Cancer Registry Profile Page
Somme Cancer Registry
Europe
Voting

Contact Info

CHU Amiens
AREREP
Bâtiment de Santé publique, 1er étage
place Victor Pauchet
Amiens cedex 01
80054
France (metropolitan)
Prof. Olivier Ganry

Description

Registration area

The Somme Cancer Registry covers the department of Somme in the Picardy region of France. The western half of Somme is both rural and industrial, with a large industrial area around the city of Amiens. Cereal and industrial crops are grown in the east. In 2013, the population was 571 000, with 133 000 residents in Amiens and fewer than 30 000 residents in each of the other towns.

Cancer care facilities

Cancer treatment is provided in six towns in Somme, in regional university hospitals, general hospitals, and clinics. There are no cancer centres, but chemotherapy and radiotherapy are offered at two institutions. In 90% of cases, residents are treated entirely within the registration area. Multidisciplinary consultation meetings have become essential for the organization of care.

Registry structure and methods

The registry is subject to the French Associations Bill of 1901. It is funded by the Institute for Public Health Surveillance, the National Cancer Institute, the departmental committee of the French League Against Cancer, and the Regional Council of Picardy. It is part of the French network of cancer registries (FRANCIM). The registry employs an epidemiologist, a technical director, four cancer registrars, and a data manager. Cancer is not a reportable disease. Data are actively collected from medical and administrative records, and 94 additional sources are solicited for notifications. The registrars consult medical and administrative files to validate and update incident cases. All identifying information is confidential, and the registry’s operation is monitored by the National Commission on Information Technology and Civil Liberties. Regular data checks ensure quality and consistency, and data quality is verified every 4 years by the National Committee of Registries.

Interpreting the results

The registry began using new sources in the 2000s, which improved data completeness. Screening programmes for breast and colorectal cancers began in 1990 and 2007, respectively. Prostate-specific antigen (PSA) testing was introduced in 1996.

Use of the data

The registry publishes descriptive epidemiology analyses and performs studies both independently and in collaboration with other registries. The registry is a member of the regional oncology network, and its data are used for planning and developing care and screening programmes.

Photos

This tab contains a basic no-frills image Gallery for CB profiles

No Items published in this profile gallery
 

Presentations

Reports

Standard Tables

Our partners

120507 01b LOGO X3

 

iarc-logo

 

encr-logo

This website was developed and is hosted at the International Agency for Research on Cancer (IARC)
Go to top